Ernährungsempfehlungen bei chronischer Niereninsuffizienz

2018 ◽  
Vol 22 (10) ◽  
pp. 448-452
Author(s):  
Rainer Stange
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Chronische Niereninsuffizienz ◽  
Omega 3

ZusammenfassungEine den CKD-Krankheitsstadien (CKD: chronic kidney disease, chronische Niereninsuffizienz) angepasste Ernährung kann das dialysefreie Intervall und die Lebensqualität günstig beeinflussen. Da der Ruheenergieumsatz der Nieren circa 7 % beträgt, sollte die Proteinzufuhr zwischen 6 und 8 g/d kg KG betragen. Ein prognostisch ungünstiger Faktor sind auch die Störungen im Säure-Basen-Haushalt, die zum Beispiel durch Gabe von basischen Salzen ausgeglichen werden sollten. Eine Kochsalzzufuhr von weniger als 5,5 g/d kann den Blutdruck und die Osteoporose günstig beeinflussen. Auf die Progression können sich auch L-Arginin, Omega-3-Fettsäuren und Folsäure auswirken. Regelmäßige Ernährungsberatungen und Kontrollen sind empfehlenswert.

scholarly journals Effect of the association of diet, omega-three, and antioxidants in dogs with chronic kidney disease

2015 ◽  
Vol 36 (5) ◽  
pp. 3161
Author(s):  
Pillar Gomide do Valle ◽  
Júlio César Cambraia Veado ◽  
Tathiana Mourão dos Anjos ◽  
Luiz Eduardo Souza de Tassini ◽  
Luiz Fernando Lucas Ferreira ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Omega 3

<p> </p><p><span><span>Para avaliar a contribuição da combinação de drogas de ômega-3, vitamina E, selenito de sódio, gluconato de cobre, gluconato de zinco, sulfato de condroitina, glucosamina e (Gerioox®), 12 cães com doença renal crônica (DRC) em atendimento clínico ambulatorial no Foram estudados hospital veterinário de uma instituição federal de ensino superior. </span><span>Contagens completas de sangue, urinálise, medições da concentração sérica de cálcio, fósforo, ureia e creatinina, e os cálculos da proteína urinária de creatinina (UPC) e taxa de filtração glomerular (TFG) foram realizados antes do início da experiência (T0) e depois 30 (T1), 90 (T2), e 120 dias (T3). </span><span>Houve uma correlação negativa significativa (P &lt;0,05) entre o TFG ea UPC e entre o TFG ea uréia e creatinina séricas (quando a GFR foi alta, a UPC, uréia e creatinina séricas foram diminuídos). </span><span>A melhora foi observada no estado clínico dos pacientes estudados, conforme relatado pelos seus proprietários, que indicaram uma melhoria na vitalidade e apetite, e pela observação clínica, que mostrou melhora no estado geral de saúde, casaco, e os parâmetros analisados. </span><span>A combinação de omega-3, a vitamina E, o selenito de sódio, gluconato de cobre, gluconato de zinco, sulfato de condroitina, glucosamina e encontrado em Gerioox® provou ser um adjuvante importante no tratamento conservador de cães com DRC, causando um aumento na taxa de filtração glomerular com uma redução na proteinúria. </span><span>Este resultado indica que houve uma melhoria na qualidade de excreção, e não um aumento na excreção de si, o que é um resultado do efeito indesejado de aumento da pressão glomerular.</span></span></p>

scholarly journals Beneficial Effects of 6-Month Supplementation with Omega-3 Acids on Selected Inflammatory Markers in Patients with Chronic Kidney Disease Stages 1–3

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Agnieszka Pluta ◽  
Paweł Stróżecki ◽  
Jacek Kęsy ◽  
Kinga Lis ◽  
Beata Sulikowska ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Serum Concentration ◽  
Reference Group ◽  
Omega 3 ◽  
Alpha Linolenic Acid ◽  
Beneficial Effects ◽  
Markers Of Inflammation ◽  
Wbc Count

Introduction. Chronic kidney disease (CKD) is accompanied by inflammation. The aim of this study was to evaluate the effect of 6-month supplementation with omega-3 acids on selected markers of inflammation in patients with CKD stages 1–3. Methods. Six-month supplementation with omega-3 acids (2 g/day) was administered to 87 CKD patients and to 27 healthy individuals. At baseline and after follow-up, blood was taken for C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1) concentration and white blood cell (WBC) count. Serum concentration of omega-3 acids—eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA)—was determined using gas chromatography. And 24-hour urinary collection was performed to measure MCP-1 excretion. Results. After six-month omega-3 supplementation, ALA concentration increased in CKD patients and in the reference group, while EPA and DHA did not change. At follow-up, a significant decrease in urinary MCP-1 excretion in CKD (p=0.0012) and in the reference group (p=0.001) was found. CRP, serum MCP-1, and WBC did not change significantly. The estimated glomerular filtration rate (eGFR) did not change significantly in the CKD group. Conclusions. The reduction of urinary MCP-1 excretion in the absence of MCP-1 serum concentration may suggest a beneficial effect of omega-3 supplementation on tubular MCP-1 production. Trial Registration. This study was registered in ClinicalTrials.gov (identifier: NCT02147002).

scholarly journals Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

2012 ◽  
Vol 6 (1) ◽  
pp. 122-125 ◽  
Author(s):  
Vasilios G Athyros ◽  
Dimitri P Mikhailidis
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Mixed Hyperlipidemia

This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have mixed hyperlipidemia and rhabdomyolysis. Because of concerns with her chronic kidney disease (CKD), we temporarily stopped all her drug treatments and started insulin treatment for her type 2 diabetes (T2D). A month later when her T2D was stabilised, we prescribed atorvastatin and an omega-3 fatty acid ethyl ester supplement to treat her hypertriglyceridemia. Within two months her blood lipids were within the recommended range. In patients with stage 3–5 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin that is metabolised predominantly in the kidneys. To minimise adverse events without compromise on efficacy, we used a combination of omega-3 fatty acid ethyl esters, which are not metabolised in the kidneys, with a statin that is minimally metabolised in the kidneys for the treatment of her hyperlipidemia.

scholarly journals MO235EFFECT OF OMEGA-3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION ON GLYSEMIC CONTROL AND RENAL FUNCTION IN TYPE 2 DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Mehmet Usta ◽  
Alpaslan Ersoy ◽  
Canan Ersoy ◽  
Yavuz Ayar ◽  
Gultekin Goksel ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Diabetic Patients ◽  
Omega 3 ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Pufa Supplementation ◽  
Type 2 Diabetic

Abstract Background and Aims The aim of this study was to evaluate the short-term effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) supplementation on glycemic control and renal function in type 2 diabetic patients with chronic kidney disease. Method Twenty-five diabetic patients received medication containing 2 g/day n-3 PUFA orally in addition to standard treatments. Their estimated glomerular filtration rates (eGFR) were &lt;80 mL/min/1.73 m2. Biochemical values were evaluated before and 3 months after treatment. Results After three months of supplementation, the changes in serum creatinine, uric acid, eGFR and urinary albumin excretion levels did not reach statistical significance. There was no difference between serum glucose, HbA1C and lipid profile values before and after the n-3 PUFA supplementation in patients. Only serum albumin significantly increased from 4.10±0.26 to 4.28±0.31 g/dL (p=0.016), and systolic blood pressure decreased from 121.4±14.5 to 116.6±14.9 mmHg (p=0.001). Conclusion Short-term n-3 PUFA supplementation did not affect renal function and glycemic control in patients with type 2 diabetes with chronic kidney disease.

scholarly journals Omega‐3 Fatty Acids Mitigate Inflammation in Felines with Chronic Kidney Disease

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Mary A Harris ◽  
Katharine Lunn ◽  
Jessica Quimby ◽  
Susan Kim ◽  
Christopher Mulligan
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acids ◽  
Kidney Disease ◽  
Omega 3 Fatty Acids ◽  
Omega 3

Trainingstherapie in der Nephrologie

2018 ◽  
Vol 22 (10) ◽  
pp. 443-447
Author(s):  
Rolfdieter Krause ◽  
Fabian Halleck ◽  
Michal Kardasinski ◽  
Bernd Wolfarth ◽  
Klemens Budde
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Koronare Herzkrankheit ◽  
Chronische Niereninsuffizienz ◽  
Aktivitäten Des Täglichen Lebens ◽  
Körperliche Aktivitäten

ZusammenfassungDie chronische Niereninsuffizienz (Chronic Kidney Disease, CKD) führt über mehrere Folge- und Begleiterkrankungen zu körperlicher Leistungsminderung, die bis zur Dialysepflichtigkeit einen Abfall um 60–80 % betragen kann. Regelmäßige körperliche Aktivitäten können diese Leistungsminderung aufhalten und wieder verbessern. Dazu sind auch die Aktivitäten des täglichen Lebens gut geeignet, wie zum Beispiel Einkaufen- und Spazierengehen, Fahrradfahren oder Gartenarbeit. Außerdem werden bekanntermaßen koronare Herzkrankheit (KHK), Herzinsuffizienz, Hypertonie sowie Diabetes positiv beeinflusst, und es können Medikamente eingespart werden. (Heim-)Trainingsprogramme für chronisch Nierenkranke sind seit vielen Jahren bekannt und haben sich bewährt. In Deutschland ist ambulanter Rehabilitationssport auch für die chronische Niereninsuffizienz anerkannt. Eine individuell verordnete Trainingstherapie als „Rezept für Bewegung“ sollte in allen Stadien der CKD zum Standard der nephrologischen Behandlung gehören.

Sign in / Sign up

Export Citation Format

Share Document